Lenalidomide Grindeks

Monotherapy for maintenance treatment of adult patients w/ newly diagnosed multiple myeloma (NDMM) who have undergone autologous stem cell transplantation (ASCT). In combination w/ dexamethasone for previously untreated multiple myeloma patients who are ineligible for transplant; for multiple myeloma patients who have received at least 1 prior therapy.

NDMM Patient who had undergone ASCT Recommended dose: Initially 10 mg once daily continuously on days 1-28 of repeated 28-day cycles given until disease progression or intolerance. May increase dose to 15 mg once daily if tolerated after 3 cycles of lenalidomide maintenance. Patient who is ineligible for transplant Recommended dose: Initially 25 mg once daily on days 1-21 of repeated 28-day cycles. Recommended dexamethasone dose: 40 mg once daily on days 1, 8, 15 & 22 of repeated 28-day cycles. Multiple myeloma w/ at least 1 prior therapy Recommended dose: Initially 25 mg once daily on days 1-21 of repeated 28-day cycles. Recommended dexamethasone dose: 40 mg once daily on days 1-4, 9-12 & 17-20 of each 28-day cycle for 1st 4 cycles of therapy & then 40 mg once daily on days 1-4 every 28 days. Multiple myeloma Moderate renal impairment CrCl ≤30-<50 mL/min 10 mg once daily on days 1-21 of repeated 28-day cycles, severe renal impairment CrCl <30 mL/min not requiring dialysis 15 mg every other day on days 1-21 of repeated 28-day cycles, ESRD CrCl <30 mL/min requiring dialysis 5 mg once daily on days 1-21 of repeated 28-day cycles; on dialysis days, administer dose following dialysis.

May be taken with or without food: Swallow whole preferably w/ water. Do not open/break/chew.

Hypersensitivity. Women of childbearing potential unless all conditions of Pregnancy Prevention Programme are met. Pregnancy.

Cancer Immunotherapy

L04AX04 - lenalidomide ; Belongs to the class of other immunosuppressants.

POM